The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this trial is to compare blood pressure lowering efficacy of moderate Valsartan + Amlodipine treatment regimen (160 / 5 mg) with that of aggressive regimen (320 / 10 mg) in patients uncontrolled on ARB monotherapy, other than Valsartan

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin Receptor Antagonists; Hydrochlorothiazide; Valsartan